Development and in vitro analysis of a new biodegradable PLA/Hydroxyapatite (HAp) composite for biomedical applications

Macha, IJ; Ben-Nissan, B; Choi, A; Cazalbou, S

Development and in vitro analysis of a new biodegradable PLA/Hydroxyapatite (HAp) composite for biomedical applications

Macha, IJ Ben-Nissan, B Choi, A Cazalbou, S

Permalink

Publication Type:: Chapter
Citation:: Clinical Applications of Biomaterials: State-of-the-Art Progress, Trends, and Novel Approaches, 2017, pp. 411 - 423
Issue Date:: 2017-06-07

Closed Access

	Filename	Description	Size
	PAC-10019045.pdf	Published version	557.64 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Macha, IJ	en_US
dc.contributor.author	Ben-Nissan, B	en_US
dc.contributor.author	Choi, A	en_US
dc.contributor.author	Cazalbou, S	en_US
dc.date.issued	2017-06-07	en_US
dc.identifier.citation	Clinical Applications of Biomaterials: State-of-the-Art Progress, Trends, and Novel Approaches, 2017, pp. 411 - 423	en_US
dc.identifier.isbn	9783319560588	en_US
dc.identifier.uri	http://hdl.handle.net/10453/127724
dc.description.abstract	© Springer International Publishing AG 2017. The development of new drugs or formulations for the treatments of different musculoskeletal disorders (MSDs) has now being a focus of pharmaceutical and scientific societies. Targeted and multidelivery of drug and key minerals to support bone repair and regeneration at the defect site, from flexible biodegradable devices at the rate within the therapeutic window, seem to be an effective strategy. However, the drug delivery vehicles available are neither flexible and degradable nor able to deliver both pharmaceutical drug and minerals effectively. The use of biodegradable polymer and bioceramic for composite development with enough flexibility and potential for slow in situ drug delivery for biomedical applications could be one of the real options to mitigate MSDs problem. In vitro analysis of the developed devices is a vital step towards clinical trial and commercialization of the implant. Different approach and results have been compared to draw guidelines for the development and testing of thin film composite applications as a slow drug delivery vehicle.	en_US
dc.relation.ispartof	Clinical Applications of Biomaterials: State-of-the-Art Progress, Trends, and Novel Approaches	en_US
dc.relation.isbasedon	10.1007/978-3-319-56059-5_13	en_US
dc.title	Development and in vitro analysis of a new biodegradable PLA/Hydroxyapatite (HAp) composite for biomedical applications	en_US
dc.type	Chapter
utslib.for	0903 Biomedical Engineering	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	closed_access
pubs.publication-status	Published	en_US

Abstract:

© Springer International Publishing AG 2017. The development of new drugs or formulations for the treatments of different musculoskeletal disorders (MSDs) has now being a focus of pharmaceutical and scientific societies. Targeted and multidelivery of drug and key minerals to support bone repair and regeneration at the defect site, from flexible biodegradable devices at the rate within the therapeutic window, seem to be an effective strategy. However, the drug delivery vehicles available are neither flexible and degradable nor able to deliver both pharmaceutical drug and minerals effectively. The use of biodegradable polymer and bioceramic for composite development with enough flexibility and potential for slow in situ drug delivery for biomedical applications could be one of the real options to mitigate MSDs problem. In vitro analysis of the developed devices is a vital step towards clinical trial and commercialization of the implant. Different approach and results have been compared to draw guidelines for the development and testing of thin film composite applications as a slow drug delivery vehicle.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/127724